Self-Cut Mesh Noninferior for Pelvic Organ Prolapse Procedure
WEDNESDAY, Sept. 21, 2022 (HealthDay News) -- Using the same titanium-coated polypropylene mesh, the surgical success rate with self-cut mesh is noninferior to that with a commercial mesh kit for the transvaginal treatment of severe pelvic organ prolapse (POP), according to a study published online Sept. 16 in JAMA Network Open.
Juan Chen, M.D., Ph.D., from the Chinese Academy of Medical Science and Peking Union Medical College in Beijing, and colleagues conducted a randomized clinical trial to assess the one-year effectiveness and safety of self-cut titanium-coated polypropylene mesh (169 patients) versus a precut commercial mesh kit (167 patients) for the transvaginal surgical treatment of women with severe symptomatic POP.
The researchers found that 95.9 percent in the self-cut mesh group met the definition of surgical success, which was noninferior to the surgical success rate achieved in the mesh-kit group (87.4 percent). There was no significant difference in the frequency of Clavien-Dindo grade 1 to 3 perioperative complications (7.2 percent in the self-cut mesh group versus 12.4 percent in the mesh-kit group). At one year, vaginal mesh exposure rates were similar (2.4 percent in the self-cut mesh group versus 4.8 percent in the mesh-kit group). Finally, there was a savings of $2,481.00 (40.4 percent) with the use of self-cut mesh when comparing median total hospitalization costs.
"Self-cut mesh procedures may be advantageous for some patients in countries with low and middle income," the authors write.
Related Posts
One in Four People With Diabetes Worldwide Have Osteoporosis
TUESDAY, Jan. 31, 2023 (HealthDay News) – More than one-quarter of people with...
Death Common During, Within One Month of Emergency Visit
FRIDAY, Nov. 4, 2022 (HealthDay News) -- Deaths during or shortly after...
AUA: Genomic Urine Test Accurately Predicts Bladder Cancer
MONDAY, May 15, 2023 (HealthDay News) – A new genomic urine test can predict...
Transient Benefit in Outcomes Seen With Androgen Suppression + RT for Prostate Cancer
WEDNESDAY, May 24, 2023 (HealthDay News) -- For patients with intermediate-risk...